High-frequency Variants in PKA Signaling-related Genes Within a Large Pediatric Cohort with Obesity or Metabolic Abnormalities

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2023 Nov 29

PMID 38027204

Authors

Michelle Bloyd

Ninet Sinaii

Fabio Rueda Faucz

James Iben

Steven L Coon

Sonia Caprio

Nicola Santoro

Constantine A Stratakis

Edra London

Affiliations

Soon will be listed here.

Abstract

Introduction: Pediatric obesity has steadily increased in recent decades. Large-scale genome-wide association studies (GWAS) conducted primarily in Eurocentric adult populations have identified approximately 100 loci that predispose to obesity and type II diabetes. GWAS in children and individuals of non-European descent, both disproportionately affected by obesity, are fewer. Rare syndromic and monogenic obesities account for only a small portion of childhood obesity, so understanding the role of other genetic variants and their combinations in heritable obesities is key to developing targeted and personalized therapies. Tight and responsive regulation of the cAMP-dependent protein kinase (PKA) signaling pathway is crucial to maintaining healthy energy metabolism, and mutations in PKA-linked genes represent the most common cause of monogenic obesity.

Methods: For this study, we performed targeted exome sequencing of 53 PKA signaling-related genes to identify variants in genomic DNA from a large, ethnically diverse cohort of obese or metabolically challenged youth.

Results: We confirmed 49 high-frequency variants, including a novel variant in the PDE11A gene (c.152C>T). Several other variants were associated with metabolic characteristics within ethnic groups.

Discussion: We conclude that a PKA pathway-specific variant search led to the identification of several new genetic associations with obesity in an ethnically diverse population.

References

Horvath A, Boikos S, Giatzakis C, Robinson-White A, Groussin L, Griffin K . A genome-wide scan identifies mutations in the gene encoding phosphodiesterase 11A4 (PDE11A) in individuals with adrenocortical hyperplasia. Nat Genet. 2006; 38(7):794-800. DOI: 10.1038/ng1809. View

Velazquez-Roman J, A Angulo-Zamudio U, Leon-Sicairos N, Medina-Serrano J, DeLira-Bustillos N, Villamil-Ramirez H . Association of FTO, ABCA1, ADRB3, and PPARG variants with obesity, type 2 diabetes, and metabolic syndrome in a Northwest Mexican adult population. J Diabetes Complications. 2021; 35(11):108025. DOI: 10.1016/j.jdiacomp.2021.108025. View

de Ferranti S, Steinberger J, Ameduri R, Baker A, Gooding H, Kelly A . Cardiovascular Risk Reduction in High-Risk Pediatric Patients: A Scientific Statement From the American Heart Association. Circulation. 2019; 139(13):e603-e634. DOI: 10.1161/CIR.0000000000000618. View

Fan W, Boston B, Kesterson R, Hruby V, Cone R . Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature. 1997; 385(6612):165-8. DOI: 10.1038/385165a0. View

Kroon J, Pereira A, Meijer O . Glucocorticoid Sexual Dimorphism in Metabolism: Dissecting the Role of Sex Hormones. Trends Endocrinol Metab. 2020; 31(5):357-367. DOI: 10.1016/j.tem.2020.01.010. View

Liang C, Li Y, Bai M, Huang Y, Yang H, Liu L . Hypericin attenuates nonalcoholic fatty liver disease and abnormal lipid metabolism via the PKA-mediated AMPK signaling pathway in vitro and in vivo. Pharmacol Res. 2020; 153:104657. DOI: 10.1016/j.phrs.2020.104657. View

Noureddin M, Sanyal A . Pathogenesis of NASH: The Impact of Multiple Pathways. Curr Hepatol Rep. 2019; 17(4):350-360. PMC: 6677539. DOI: 10.1007/s11901-018-0425-7. View

Stratakis C . Cushing syndrome caused by adrenocortical tumors and hyperplasias (corticotropin- independent Cushing syndrome). Endocr Dev. 2008; 13:117-132. PMC: 3132884. DOI: 10.1159/000134829. View

Omar B, Banke E, Ekelund M, Frederiksen S, Degerman E . Alterations in cyclic nucleotide phosphodiesterase activities in omental and subcutaneous adipose tissues in human obesity. Nutr Diabetes. 2013; 1:e13. PMC: 3302168. DOI: 10.1038/nutd.2011.9. View

10.

van den Berg L, van Beekum O, Heutink P, Felius B, van de Heijning M, Strijbis S . Melanocortin-4 receptor gene mutations in a Dutch cohort of obese children. Obesity (Silver Spring). 2010; 19(3):604-11. DOI: 10.1038/oby.2010.259. View

11.

Bloyd M, Settas N, Rueda Faucz F, Sinaii N, Bathon K, Iben J . The PRKAR1B p.R115K Variant is Associated with Lipoprotein Profile in African American Youth with Metabolic Challenges. J Endocr Soc. 2021; 5(8):bvab071. PMC: 8237845. DOI: 10.1210/jendso/bvab071. View

12.

Cuffe H, Liu M, Key C, Boudyguina E, Sawyer J, Weckerle A . Targeted Deletion of Adipocyte Abca1 (ATP-Binding Cassette Transporter A1) Impairs Diet-Induced Obesity. Arterioscler Thromb Vasc Biol. 2018; 38(4):733-743. PMC: 5864538. DOI: 10.1161/ATVBAHA.117.309880. View

13.

Langenberg C, Lotta L . Genomic insights into the causes of type 2 diabetes. Lancet. 2018; 391(10138):2463-2474. DOI: 10.1016/S0140-6736(18)31132-2. View

14.

Lawrence J, Divers J, Isom S, Saydah S, Imperatore G, Pihoker C . Trends in Prevalence of Type 1 and Type 2 Diabetes in Children and Adolescents in the US, 2001-2017. JAMA. 2021; 326(8):717-727. PMC: 8385600. DOI: 10.1001/jama.2021.11165. View

15.

Valaiyapathi B, Gower B, Ashraf A . Pathophysiology of Type 2 Diabetes in Children and Adolescents. Curr Diabetes Rev. 2018; 16(3):220-229. PMC: 7516333. DOI: 10.2174/1573399814666180608074510. View

16.

Ceyhan O, Birsoy K, Hoffman C . Identification of biologically active PDE11-selective inhibitors using a yeast-based high-throughput screen. Chem Biol. 2012; 19(1):155-63. DOI: 10.1016/j.chembiol.2011.12.010. View

17.

London E, Noguchi A, Springer D, Faidas M, Gavrilova O, Eisenhofer G . The Catalytic Subunit of PKA Affects Energy Balance and Catecholaminergic Activity. J Endocr Soc. 2019; 3(5):1062-1078. PMC: 6503631. DOI: 10.1210/js.2019-00029. View

18.

Riccio S, Melone R, Vitulano C, Guida P, Maddaluno I, Guarino S . Advances in pediatric non-alcoholic fatty liver disease: From genetics to lipidomics. World J Clin Pediatr. 2022; 11(3):221-238. PMC: 9134151. DOI: 10.5409/wjcp.v11.i3.221. View

19.

Yang H, Yang L . Targeting cAMP/PKA pathway for glycemic control and type 2 diabetes therapy. J Mol Endocrinol. 2016; 57(2):R93-R108. DOI: 10.1530/JME-15-0316. View

20.

Sherif Z, Saeed A, Ghavimi S, Nouraie S, Laiyemo A, Brim H . Global Epidemiology of Nonalcoholic Fatty Liver Disease and Perspectives on US Minority Populations. Dig Dis Sci. 2016; 61(5):1214-25. PMC: 4838529. DOI: 10.1007/s10620-016-4143-0. View